Alpha-1 Antitrypsin Deficiency: Why fragmented care costs lives

Written by The Life Science Feed Editorial Team · Published 8 September 2026 · Edited by Mara Voss

Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder that often presents a diagnostic conundrum, manifesting primarily as chronic obstructive pulmonary disease (COPD) in adults and liver disease across all age groups. The dual organ involvement means patients frequently navigate a fragmented healthcare system, moving between pulmonologists and hepatologists who may not always recognize the systemic nature of the condition. This siloed approach delays diagnosis and initiation of appropriate management, highlighting a critical unmet need for integrated care strategies.

KEY TAKEAWAYS

- The Pivot: AATD requires a coordinated, multidisciplinary approach that integrates respiratory and hepatology expertise from initial suspicion through long-term management.
- The Data: Early diagnosis of AATD remains low, with many patients experiencing significant organ damage before identification.
- The Action: Clinicians should consider AATD screening in all patients with unexplained COPD, non-alcoholic fatty liver disease (NAFLD) without typical risk factors, or any unexplained liver dysfunction.

Alpha-1 antitrypsin deficiency is an inherited disorder characterized by low serum levels of alpha-1 antitrypsin (AAT), a protease inhibitor primarily synthesized in the liver. This deficiency leads to two main pathological processes: uncontrolled elastase activity in the lungs, causing progressive destruction of alveolar walls and emphysema, and accumulation of misfolded AAT protein polymers within hepatocytes, resulting in liver damage ranging from neonatal cholestasis to cirrhosis and hepatocellular carcinoma. The severity of the disease is largely determined by specific genetic variants, with the Pi*Z allele being the most common severe deficiency allele.

Patients with AATD often present with respiratory symptoms such as dyspnea, chronic cough, and wheezing, typically in their third or fourth decade, often misdiagnosed as conventional COPD or asthma. Liver manifestations can appear at any age, from prolonged neonatal jaundice to cryptogenic cirrhosis in adulthood. The insidious onset and variable presentation across organ systems contribute to significant diagnostic delays, with the average time from symptom onset to diagnosis often exceeding five years. This delay is particularly problematic as irreversible organ damage, especially in the lungs, progresses during this period.

The Molecular Basis of Disease

The alpha-1 antitrypsin protein is encoded by the SERPINA1 gene. Over 100 different alleles have been identified, but the most clinically significant are the M, S, and Z alleles. The M allele is associated with normal AAT levels and function.

The S allele leads to moderately reduced AAT levels, typically not causing significant disease unless combined with another deficient allele. The Z allele, however, is responsible for the most severe form of AATD. Individuals homozygous for the Z allele (Pi*ZZ) produce a mutant AAT protein that misfolds and polymerizes within the endoplasmic reticulum of hepatocytes. This intracellular accumulation prevents adequate secretion into the bloodstream, leading to very low circulating AAT levels.

The consequences of this molecular defect are twofold. In the liver, the retained misfolded protein aggregates trigger a stress response, leading to hepatocyte injury, inflammation, fibrosis, and ultimately cirrhosis. This process can begin in childhood, with some infants presenting with cholestatic jaundice. In adults, liver disease may manifest as elevated transaminases, fatty liver, or cryptogenic cirrhosis. The risk of hepatocellular carcinoma is also significantly increased in individuals with AATD-related cirrhosis. For a deeper understanding of liver pathologies, clinicians might consult Sherlock's Diseases of the Liver and Biliary System.

In the lungs, the severe deficiency of circulating AAT leaves the delicate alveolar structures vulnerable to proteolytic enzymes, particularly neutrophil elastase. Neutrophils are recruited to the lungs during inflammation, releasing elastase to clear pathogens. Without sufficient AAT to neutralize this elastase, the enzyme indiscriminately degrades elastin and other structural components of the lung parenchyma, leading to panacinar emphysema. This differs from typical smoking-related centrilobular emphysema, often affecting the lung bases more prominently. The relentless destruction of lung tissue results in irreversible airflow obstruction and progressive respiratory failure.

Current Diagnostic and Management Guidelines

Diagnosis of AATD typically involves measuring serum AAT levels. If levels are low, genetic testing (phenotyping or genotyping) is performed to identify the specific SERPINA1 alleles. Current guidelines recommend screening for AATD in all patients with COPD, irrespective of smoking history, and in individuals with unexplained liver disease. Despite these recommendations, screening rates remain suboptimal, contributing to the significant diagnostic delay. Many clinicians, particularly in primary care, may not immediately consider AATD in the differential diagnosis for common respiratory or liver complaints.

Management strategies for AATD are largely organ-specific. For lung disease, augmentation therapy with purified human AAT is the only disease-specific treatment available. This intravenous therapy aims to replenish circulating AAT levels, thereby increasing the protective shield against elastase in the lungs. Augmentation therapy has been shown to slow the decline in lung function in patients with established emphysema, particularly those with moderate airflow obstruction. But it does not reverse existing damage and is not indicated for liver disease. Smoking cessation is paramount for all patients with AATD-related lung disease, as smoking significantly accelerates disease progression.

For liver disease, management is primarily supportive, focusing on preventing complications of cirrhosis. This includes surveillance for hepatocellular carcinoma, management of portal hypertension, and liver transplantation for end-stage liver disease. There are currently no approved therapies that directly target the accumulation of misfolded AAT protein in hepatocytes. This represents a major unmet need, especially for patients who develop severe liver disease in childhood or early adulthood. The dual organ involvement necessitates a coordinated approach, yet specialists often focus on their respective organ systems without a unified strategy.

The Unmet Need for Integrated Care

The fragmented nature of AATD care creates substantial challenges. A patient presenting with early respiratory symptoms might be managed by a pulmonologist who may not routinely screen for AATD or consider potential liver involvement. Conversely, a hepatologist treating cryptogenic cirrhosis might not inquire about respiratory symptoms or recognize the need for lung function monitoring. This lack of integration can lead to missed opportunities for early intervention, delayed augmentation therapy for lung disease, or inadequate surveillance for liver complications.

But the problem extends beyond diagnosis. Even after diagnosis, ongoing management requires a collaborative effort. Pulmonologists need to be aware of the potential for liver complications and ensure appropriate monitoring, while hepatologists must understand the implications of lung disease and advocate for respiratory assessment. The complexity of managing both aspects of the disease often falls to the patient, who must navigate multiple specialists and ensure continuity of information. This is where a comprehensive understanding of internal medicine, such as that found in the Harrison's Principles of Internal Medicine, becomes invaluable for coordinating care.

The lack of a unified approach also impacts research and drug development. Clinical trials often focus on either lung or liver endpoints, rather than addressing the systemic nature of the disease. This makes it challenging to develop therapies that could benefit both organ systems or to assess the overall impact of interventions on patient quality of life and survival. The need for a more holistic perspective in clinical trial design is evident. Our previous coverage on severe asthma treatment decisions highlights a similar shift towards broader considerations beyond single-organ focus.

Moving Towards a Multidisciplinary Model

Establishing multidisciplinary clinics or integrated care pathways for AATD could significantly improve patient outcomes. Such centers would bring together pulmonologists, hepatologists, geneticists, and other specialists to provide comprehensive assessment, diagnosis, and management under one roof. This model would facilitate timely screening, ensure appropriate initiation of augmentation therapy, and coordinate surveillance for both lung and liver complications. It would also provide a platform for patient education and support, empowering individuals to better manage their complex condition.

The implementation of such models requires a concerted effort from healthcare systems, professional societies, and patient advocacy groups. Education campaigns targeting primary care physicians and specialists are vital to raise awareness about AATD and the importance of early diagnosis. Promoting routine screening in at-risk populations, as outlined in existing guidelines, is a fundamental step. The challenge lies in overcoming inertia and established clinical practices that tend to compartmentalize disease management by organ system.

Still, the long-term benefits of an integrated approach are clear. Early diagnosis and comprehensive management can slow disease progression, improve quality of life, and potentially reduce the need for costly interventions like lung or liver transplantation. The economic burden of AATD, driven by chronic disease management and hospitalizations, is substantial. A proactive, integrated approach could mitigate some of these costs by preventing advanced disease. The lessons from managing other complex chronic conditions, such as those discussed in our article on epithelial dysfunction in airway disease, underscore the value of unified targets and integrated strategies.

The open-label design of many observational studies in AATD is an obvious caveat when assessing long-term outcomes, as is the inherent difficulty in establishing clear cause-and-effect relationships in a slowly progressive genetic disorder. The relatively small patient population also limits the power of clinical trials to detect subtle differences in disease progression or treatment efficacy across diverse subgroups. Whether benefits of augmentation therapy extend to all

genotypes or to those with very mild lung disease remains unclear, and that gap matters for clinical decision-making. The field needs more robust, prospective studies that account for the dual organ involvement and the genetic heterogeneity of AATD.

CLINICAL IMPLICATIONS

The persistent diagnostic delay in alpha-1 antitrypsin deficiency is a clinical failure. GPs and specialists alike must adopt a lower threshold for screening, particularly in patients presenting with unexplained COPD or liver dysfunction. Waiting for advanced emphysema or cirrhosis before considering AATD means irreversible damage has already occurred, limiting the impact of available therapies.

Pulmonologists and hepatologists cannot afford to operate in silos. A patient with AATD is not merely a lung patient or a liver patient; they are both. Integrated care pathways, even if informal, are essential to ensure comprehensive monitoring and timely intervention for both organ systems. This requires a shift in mindset, moving beyond organ-specific expertise to a more holistic understanding of genetic disease.

The industry's focus on augmentation therapy for lung disease, while valuable, leaves a significant gap in addressing the hepatic manifestations. There is a clear need for therapies that target the underlying mechanism of misfolded protein accumulation in the liver. Until such treatments emerge, supportive care and vigilant surveillance for hepatocellular carcinoma remain the only options for liver disease.

Improving outcomes for AATD patients hinges on proactive identification and coordinated, multidisciplinary management. The current state of fragmented care is simply inadequate for a systemic genetic disorder with such profound and varied clinical consequences.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. 1. Dasí F. Alpha-1 antitrypsin deficiency. Med Clin (Barc). 2024;162(7):336-342. doi:10.1016/j.medcli.2023.10.014
2. 2. Strnad P, McElvaney NG, Lomas DA. Alpha(1)-Antitrypsin Deficiency. N Engl J Med. 2020;382(15):1443-1455. doi:10.1056/NEJMra1910234
3. 3. de Vos JD, Hillberg O, Perch M, Jensen JU, Wilcke JT, Løkke A. [Alpha-1-antitrypsin deficiency]. Ugeskr Laeger. 2021;183(30). PMID:34356027
4. 4. Mornex JF. [Alpha 1-antitrypsin deficiency]. Rev Mal Respir. 2022;39(8):698-707. doi:10.1016/j.rmr.2022.02.062
5. 5. Fähndrich S, Bals R. [Alpha 1-antitrypsin deficiency]. Inn Med (Heidelb). 2024;65(6):533-537. doi:10.1007/s00108-024-01722-2
6. 6. Perlmutter DH. Alpha-1-antitrypsin deficiency. Semin Liver Dis. 1998;18(3):217-25. doi:10.1055/s-2007-1007158

LICENCE & RIGHTS

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com